The role of CD19+ CD5+ CD1dhi B cells in dextran sulfact sodium (DSS)

Luman Wang,Jing Qian,Xiaoming Liu,Lijun Chang,Yiwei Chu
DOI: https://doi.org/10.3969/j.issn.1672-8467.2013.01.002
2013-01-01
Abstract:Objective: To investigate the change in cell number of CD19+ CD5+ CD1dhi B cells and its function in dextran sulfate sodium (DSS) induced inflammatory bowel disease (IBD) C57BL/6 mouse model. Methods: The murine model of inflammatory bowel disease was set up by DSS treatment. Splenic CD19+ CD5+ CD1dhi B cells were harvested from mice during different disease stages, and were analyzed by flow cytometry. CD19+ CD5+ CD1dhi B cells were adoptively transferred to the DSS-treated mice, then clinical symptom was evaluated and the production of inflammatory cytokines in local intestine was detected. Results: The proportion of CD19+ CD5+ CD1dhi B cells was increased in the acute phase (Day 0-10) of the disease and returned to baseline in the recovery phase (Day 12). Adoptive transfer of CD19+ CD5+ CD1dhi B cells from mice in acute phase (Day 8) remarkably inhibited the production of proinflammatory cytokines (IFN-γ, TNF-α and IL-6) in local intestine and resolved the inflammation. Conclusions: The proportion of CD19+ CD5+ CD1dhi B cells in DSS-induced inflammatory bowel disease changed kinetically in different phases of IBD.CD19+ CD5+ CD1dhi B cells can alleviate 1BD by inhibiting the secretion of inflammatory cytokine in local intestine.
What problem does this paper attempt to address?